Arca
Skip to content

Malignant pleural mesothelioma

Drug research and approvals for malignant pleural mesothelioma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 48 studies of malignant pleural mesothelioma are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, FDA has 3 approved and 1 open orphan designations naming it, and the EU has 5 authorised medicines for it.

  • Recruiting worldwide: 48
  • Trials authorized in Canada: 6
  • FDA orphan approvals: 3
  • EU medicines: 5

Recruiting Now

Newest start dates first, of 48 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Mar 30, 2020Phase III randomized trial of pleurectomy/decortication plus chemotherapy with or without adjuvant hemithoracic intensity-modulated pleural radiation therapy…PEMETREXED/CISPLATIN/CARBOPLATINNRG ONCOLOGYClosed
Mar 7, 2019A phase III, open label, randomized, parallel group study to evaluate the efficacy and safety of intrapleural administration of adenovirus-delivered interferon…RAD-IFN (NADOFARAGENE FIRADENOVEC)/ CELECOXIB/ GEMCITABINEFerring PharmaceuticalsClosed
Dec 4, 2015A randomized, open-label, active-controlled, phase II study of intravenous anetumab ravtansine (bay 94-9343) or vinorelbine in patients with advanced or…BAY 94-9343 (ANETUMAB RAVTANSINE) / VINORELBINEBayerClosed
Aug 7, 2013A phase 2, randomized, double-blind study comparing tremelimumab to placebo in second or third-line treatment of subjects with unresectable pleural or…TREMELIMUMABMEDIMMUNE LLCPending
Aug 1, 2013A phase II randomized, double-blind, placebo-controlled, multicenter study of vs 6063 in subjects with malignant pleural mesotheliomaVS-6063Verastem, Inc.Ongoing
May 24, 2013Double blind, randomised, multicentre, phase II study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy…NINTEDANIB (BIBF 1120 ES)BOEHRINGER INGELHEIM (CANADA) LTD LTEEClosed

FDA Orphan Designations

Approved first, then open designations, newest first
Oct 2, 2020OPDIVO and YERVOYOPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural…Bristol-Myers Squibb CompanyApproved
Oct 2, 2020OPDIVO and YERVOYYERVOY (ipilimumab), in combination with nivolumab, is indicated for the first-line treatment of adult patients with unresectable malignant…Bristol-Myers Squibb CompanyApproved
Feb 4, 2004AlimtaTreatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for…Eli Lilly and CompanyApproved
Aug 22, 2008ArenegyrTreatment of malignant pleural mesotheliomaMolMed S.p.A.Designated

Medicines Authorised in the EU

Newest first
Jul 22, 2016Pemetrexed Fresenius Kabipemetrexed · genericFresenius Kabi Deutschland GmbHEMA ↗
Jan 18, 2016Pemetrexed Accordpemetrexed · genericAccord Healthcare S.L.U.EMA ↗
Jan 18, 2016Armisarte (previously Pemetrexed Actavis)pemetrexedActavis Group PTC ehfEMA ↗
Nov 19, 2015Pemetrexed Pfizer (previously Pemetrexed Hospira)pemetrexed · genericPfizer Europe MA EEIGEMA ↗
Sep 20, 2004AlimtapemetrexedEli Lilly Nederland B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.